Enzon Pharmaceuticals (ENZN) 0.97 $ENZN
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Grand Hyatt Kauai chooses Motorola Solutions' wireless access infrastructure
M2 Airline Industry Information - Wed Dec 18, 8:25AM CST
18 December 2013
Global Thymus Cancer Clinical Trials Review - H2 2013
M2 - Wed Dec 11, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxl3x9/thymus_cancer) has announced the addition of the "Thymus Cancer Global Clinical Trials Review, H2, 2013" report to their offering. Thymus Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thymus Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thymus Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thymus Cancer Therapeutics Clinical Trials - Novartis AG - Nerviano Medical Sciences S.r.l. - ZIOPHARM Oncology, Inc. - Enzon Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Stanford University - Indiana University School of Medicine - Eastern Cooperative Oncology Group - Memorial Sloan Kettering Cancer Center - Shanghai Chest Hospital - Samsung Medical Center - Faculty of Pharmaceutical Sciences, Chulalongkorn University - Roswell Park Cancer Institute - Valley Health System For more information visit http://www.researchandmarkets.com/research/kx...mus_cancer
Arthur J. Higgins Joins Endo Board of Directors
PR Newswire - Tue Dec 10, 8:50PM CST
Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013.
Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc.
PR Newswire Europe - Mon Oct 28, 7:02AM CDT
HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Company and its long term partner, Enzon Pharmaceutical Inc., have agreed that all rights, data, products and intellectual properties relating to Enzon Pharmaceutical Inc.'s LNA programs, developed under a license from Santaris Pharma A/S, will revert to Santaris Pharma A/S. Further Enzon Pharmaceutical Inc. will transfer an undisclosed amount to Santaris Pharma A/S.
Research and Markets: Enzon Pharmaceuticals Partnering 2005-2013
Business Wire - Thu Jul 18, 4:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pnw9sp/enzon) has announced the addition of the "Enzon Pharmaceuticals Partnering 2005-2013" company profile to their offering.
Enzon Pharmaceuticals Partnering 2005-2013
M2 - Thu Jul 18, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56n7m6/enzon) has announced the addition of the "Enzon Pharmaceuticals Partnering 2005-2013" company profile to their offering. The Partnering Agreements with Enzon Pharmaceuticals 2005-2013 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Key Topics Covered Executive Summary 1 - Introduction 2 - Biopharma top 50 and dealmaking activity 2.1 Biopharma partnering activity 2.2 Biopharma M&A activity 3 - Top bigpharma deals by value 3.1 Bigpharma M&A 3.2 Bigpharma partnering 4 - Submitting Opportunities to Prospective Partners 4.1 How to submit an opportunity 4.2 Opportunity submission template 4.3 Sending emails 4.4 Face to face at partnering events 4.5 Online submission forms 5 - Forthcoming partnering events 6 - Company Profile 6.1 How to use company profiles 6.2 Field definitions 6.3 Company profile Partnering deals directory (2005-present) - by industry sector Partnering deals directory (2005-present) - By deal type Partnering deals directory (2005-present) - M&A Partnering deals directory (2005-present) - By stage of development Partnering deals directory (2005-present) - By therapy area For more information visit http://www.researchandmarkets.com/research/56n7m6/enzon About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]
M2 - Tue Jun 04, 12:38PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhjbwz/biological) has announced the addition of Supplier Relations US, LLC's updated report "Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]" to their offering. This 169-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through March 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. The industry's revenue for the year 2012 was reported at $23.7 billion USD, with an estimated gross profit of 59.01%. Import was valued at $11.0 billion USD from 63 countries. The industry also exported $10.5 billion USD worth of merchandise to 166 cou
Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends
Marketwire - Tue Apr 23, 3:01PM CDT
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company, and that its Board of Directors has approved a $1.60 special dividend per share and intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to shareholders. The record date of the special dividend will be May 7, 2013, and the payment date will be June 4, 2013. Furthermore, the Company has minimized expenses and will look to maximize the return of royalty revenues to shareholders going forward.
WEALTHMAKERS.COM Issues Bullish Research Reports on CATY, CNI, DHR, ELB, ENZN, GFF
M2 - Thu Apr 11, 10:37AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Cathay General Bancorp (NASDAQ:CATY), CANADIAN NATL RAILWAY CO (NYSE:CNI), Danaher Corp (NYSE
HR), Entergy Louisiana LLC First Mortgage Bonds 6.00% Series 2040 (NYSE:ELB), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Griffon Corp (NYSE:GFF)
WEALTHMAKERS.COM Issues Bullish Research Reports on BTE, CAJ, CNI, DHR, ENZN, GFF
M2 - Thu Apr 11, 2:07AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Baytex Energy Corp (NYSE:BTE), Canon Inc (NYSE:CAJ), CANADIAN NATL RAILWAY CO (NYSE:CNI), Danaher Corp (NYSE HR), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Griffon Corp (NYSE:GFF)
WEALTHMAKERS.COM Issues Bullish Research Reports on ANSS, CHS, DY, EL, ENZN, HSIC
M2 - Wed Apr 03, 10:36AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: ANSYS Inc (NASDAQ:ANSS), Chico's FAS Inc (NYSE:CHS), Dycom Industries Inc (NYSE Y), ESTEE LAUDER COMPANIES-CL A (NYSE:EL), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Henry Schein Inc (NASDAQ:HSIC)
WEALTHMAKERS.COM Issues Bullish Research Reports on ENZN, EOC, EQIX, FAST, GRPN, KGJI
M2 - Mon Mar 25, 10:38AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Empresa Nacional de Electricidad SA (NYSE:EOC), Equinix Inc (NASDAQ:EQIX), Fastenal Co (NASDAQ:FAST), Groupon Inc (NASDAQ:GRPN), Kingold Jewelry Inc (NASDAQ:KGJI)
Enzon Reports Fourth Quarter and Full Year 2012 Results
Marketwire - Mon Mar 18, 4:08PM CDT
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth quarter and full year 2012. For the three months ended December 31, 2012, Enzon reported a loss from continuing operations of $5.2 million, or $0.11 per diluted share, compared to a loss from continuing operations of $5.0 million, or $0.10 per diluted share, for the three months ended December 31, 2011. For the full year ended December 31, 2012, Enzon reported a loss from continuing operations of $2.8 million, or $0.06 per diluted share, compared to a loss from continuing operations of $20.8 million, or $0.40 per diluted share, for the full year ended December 31, 2011. For the year ended December 31, 2012, Enzon recorded $11.3 million of non-cash impairment charges primarily related to leasehold improvements representing the Company's process development laboratory and related equipment. The charges were considered necessary in view of the Company's December 2012 announcement of plans to suspend all clinical dev
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 19, 8:45AM CST
Just as we examine companies each week that may be rising past their fair value , we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at...
Here's What Super-Investor Seth Klarman Has Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Fri Feb 15, 7:25PM CST
Every quarter, many money managers have to disclose what they've bought and sold, via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at investing giant Seth Klarman, who founded the Baupost...
Intestinal Cancer - Pipeline Review, H2 2012 Includes a Snapshot of the Global Therapeutic Scenario for Intestinal Cancer
M2 - Thu Jan 17, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/qkchs6/intestinal_cancer) has announced the addition of Global Markets Direct's new report "Intestinal Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Normal 0 false false false MicrosoftI
Hedge Funds Bought Navistar And These Other Stocks
meena@insidermonkey.com (Jake Mann)via The Motley Fool - Motley Fool - Sun Jan 06, 7:50AM CST
13F filings are a very complete picture of what a hedge fund has been doing, but unfortunately they are only released six to seven weeks after the end of a quarter. 13D and 13G filings, while generally restricted to smaller-cap stocks,...
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Grand Hyatt Kauai chooses Motorola Solutions' wireless access infrastructure
M2 Airline Industry Information - Wed Dec 18, 8:25AM CST
18 December 2013
Global Thymus Cancer Clinical Trials Review - H2 2013
M2 - Wed Dec 11, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxl3x9/thymus_cancer) has announced the addition of the "Thymus Cancer Global Clinical Trials Review, H2, 2013" report to their offering. Thymus Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thymus Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thymus Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thymus Cancer Therapeutics Clinical Trials - Novartis AG - Nerviano Medical Sciences S.r.l. - ZIOPHARM Oncology, Inc. - Enzon Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Stanford University - Indiana University School of Medicine - Eastern Cooperative Oncology Group - Memorial Sloan Kettering Cancer Center - Shanghai Chest Hospital - Samsung Medical Center - Faculty of Pharmaceutical Sciences, Chulalongkorn University - Roswell Park Cancer Institute - Valley Health System For more information visit http://www.researchandmarkets.com/research/kx...mus_cancer
Arthur J. Higgins Joins Endo Board of Directors
PR Newswire - Tue Dec 10, 8:50PM CST
Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013.
Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc.
PR Newswire Europe - Mon Oct 28, 7:02AM CDT
HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Company and its long term partner, Enzon Pharmaceutical Inc., have agreed that all rights, data, products and intellectual properties relating to Enzon Pharmaceutical Inc.'s LNA programs, developed under a license from Santaris Pharma A/S, will revert to Santaris Pharma A/S. Further Enzon Pharmaceutical Inc. will transfer an undisclosed amount to Santaris Pharma A/S.
Research and Markets: Enzon Pharmaceuticals Partnering 2005-2013
Business Wire - Thu Jul 18, 4:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pnw9sp/enzon) has announced the addition of the "Enzon Pharmaceuticals Partnering 2005-2013" company profile to their offering.
Enzon Pharmaceuticals Partnering 2005-2013
M2 - Thu Jul 18, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56n7m6/enzon) has announced the addition of the "Enzon Pharmaceuticals Partnering 2005-2013" company profile to their offering. The Partnering Agreements with Enzon Pharmaceuticals 2005-2013 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Key Topics Covered Executive Summary 1 - Introduction 2 - Biopharma top 50 and dealmaking activity 2.1 Biopharma partnering activity 2.2 Biopharma M&A activity 3 - Top bigpharma deals by value 3.1 Bigpharma M&A 3.2 Bigpharma partnering 4 - Submitting Opportunities to Prospective Partners 4.1 How to submit an opportunity 4.2 Opportunity submission template 4.3 Sending emails 4.4 Face to face at partnering events 4.5 Online submission forms 5 - Forthcoming partnering events 6 - Company Profile 6.1 How to use company profiles 6.2 Field definitions 6.3 Company profile Partnering deals directory (2005-present) - by industry sector Partnering deals directory (2005-present) - By deal type Partnering deals directory (2005-present) - M&A Partnering deals directory (2005-present) - By stage of development Partnering deals directory (2005-present) - By therapy area For more information visit http://www.researchandmarkets.com/research/56n7m6/enzon About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]
M2 - Tue Jun 04, 12:38PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhjbwz/biological) has announced the addition of Supplier Relations US, LLC's updated report "Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2013 Q2 Edition]" to their offering. This 169-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through March 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. The industry's revenue for the year 2012 was reported at $23.7 billion USD, with an estimated gross profit of 59.01%. Import was valued at $11.0 billion USD from 63 countries. The industry also exported $10.5 billion USD worth of merchandise to 166 cou
Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends
Marketwire - Tue Apr 23, 3:01PM CDT
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it has concluded a thorough review of the possible sale or disposition of one or more corporate assets, or a sale of the Company, and that its Board of Directors has approved a $1.60 special dividend per share and intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to shareholders. The record date of the special dividend will be May 7, 2013, and the payment date will be June 4, 2013. Furthermore, the Company has minimized expenses and will look to maximize the return of royalty revenues to shareholders going forward.
WEALTHMAKERS.COM Issues Bullish Research Reports on CATY, CNI, DHR, ELB, ENZN, GFF
M2 - Thu Apr 11, 10:37AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Cathay General Bancorp (NASDAQ:CATY), CANADIAN NATL RAILWAY CO (NYSE:CNI), Danaher Corp (NYSE
HR), Entergy Louisiana LLC First Mortgage Bonds 6.00% Series 2040 (NYSE:ELB), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Griffon Corp (NYSE:GFF) WEALTHMAKERS.COM Issues Bullish Research Reports on BTE, CAJ, CNI, DHR, ENZN, GFF
M2 - Thu Apr 11, 2:07AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Baytex Energy Corp (NYSE:BTE), Canon Inc (NYSE:CAJ), CANADIAN NATL RAILWAY CO (NYSE:CNI), Danaher Corp (NYSE
HR), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Griffon Corp (NYSE:GFF) WEALTHMAKERS.COM Issues Bullish Research Reports on ANSS, CHS, DY, EL, ENZN, HSIC
M2 - Wed Apr 03, 10:36AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: ANSYS Inc (NASDAQ:ANSS), Chico's FAS Inc (NYSE:CHS), Dycom Industries Inc (NYSE
Y), ESTEE LAUDER COMPANIES-CL A (NYSE:EL), Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Henry Schein Inc (NASDAQ:HSIC) WEALTHMAKERS.COM Issues Bullish Research Reports on ENZN, EOC, EQIX, FAST, GRPN, KGJI
M2 - Mon Mar 25, 10:38AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Empresa Nacional de Electricidad SA (NYSE:EOC), Equinix Inc (NASDAQ:EQIX), Fastenal Co (NASDAQ:FAST), Groupon Inc (NASDAQ:GRPN), Kingold Jewelry Inc (NASDAQ:KGJI)
Enzon Reports Fourth Quarter and Full Year 2012 Results
Marketwire - Mon Mar 18, 4:08PM CDT
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth quarter and full year 2012. For the three months ended December 31, 2012, Enzon reported a loss from continuing operations of $5.2 million, or $0.11 per diluted share, compared to a loss from continuing operations of $5.0 million, or $0.10 per diluted share, for the three months ended December 31, 2011. For the full year ended December 31, 2012, Enzon reported a loss from continuing operations of $2.8 million, or $0.06 per diluted share, compared to a loss from continuing operations of $20.8 million, or $0.40 per diluted share, for the full year ended December 31, 2011. For the year ended December 31, 2012, Enzon recorded $11.3 million of non-cash impairment charges primarily related to leasehold improvements representing the Company's process development laboratory and related equipment. The charges were considered necessary in view of the Company's December 2012 announcement of plans to suspend all clinical dev
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 19, 8:45AM CST
Just as we examine companies each week that may be rising past their fair value , we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at...
Here's What Super-Investor Seth Klarman Has Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Fri Feb 15, 7:25PM CST
Every quarter, many money managers have to disclose what they've bought and sold, via "13F" filings. Their latest moves can shine a bright light on smart stock picks. Today, let's look at investing giant Seth Klarman, who founded the Baupost...
Intestinal Cancer - Pipeline Review, H2 2012 Includes a Snapshot of the Global Therapeutic Scenario for Intestinal Cancer
M2 - Thu Jan 17, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/qkchs6/intestinal_cancer) has announced the addition of Global Markets Direct's new report "Intestinal Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Normal 0 false false false MicrosoftI
Hedge Funds Bought Navistar And These Other Stocks
meena@insidermonkey.com (Jake Mann)via The Motley Fool - Motley Fool - Sun Jan 06, 7:50AM CST
13F filings are a very complete picture of what a hedge fund has been doing, but unfortunately they are only released six to seven weeks after the end of a quarter. 13D and 13G filings, while generally restricted to smaller-cap stocks,...
